HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

Abroad (travel likely)RecruitingPHASE2

Conditions

Borderline Resectable Pancreatic Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou, Zhejiang, China
Contact: Study coordinator (Yiwen Chen, MD) · yiwenchen0705@126.com · 86+15088682641
the First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
Contact: Study coordinator (Yiwen Chen, MD.) · yiwenchen0705@126.com · +8619941463683
Contact: Principal Investigator (Tingbo Liang, MD. PhD.)

View source on ClinicalTrials.gov Contact study team (email)